Amgen, Inc. vs Caesars Entertainment Inc — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while Caesars Entertainment Inc trades at $29.63 (market cap $6.06B). The key difference: Amgen, Inc. is far larger — about 37× Caesars Entertainment Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Caesars Entertainment Inc pays none. Which is the better fit depends on your goals.
| AMGN | CZR | |
|---|---|---|
Market Cap | $224.14B | $6.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $30.41 |
52-Week Low | $271.18 | $18.14 |
Enterprise Value | $267.45B | $29.95B |
Dividend Yield | 2.43% | — |
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
Caesars Entertainment (CZR) trades at $29.62, down 1.5% on the day, with a bearish technical signal and recent quarterly earnings misses. The company reported a Q2 2026 loss of $0.30 per share, missing estimates, but revenue of $3.0 billion topped expectations. Fundamentals show a negative net income margin of -3.99% and high long-term debt of $12.03 billion, though operating cash flow remains strong at $1.30 billion in 2025. The pending acquisition by Tilman Fertitta for approximately $17.6 billion is a key development, as reported by the Wall Street Journal on July 28, 2026.
CZR presents a mixed outlook with acquisition potential offset by persistent losses and debt. The stock's low P/S ratio of 0.52 offers value, but investors face risks from earnings volatility and competitive pressures in the leisure sector. Analyst sentiment is cautious with 70% hold ratings, reflecting uncertainty around profitability improvements and integration post-acquisition.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →